Fig. 4: Upregulation of the Wnt/β-catenin pathway in MSCs from patients with active cGVHD. | Cell Death & Disease

Fig. 4: Upregulation of the Wnt/β-catenin pathway in MSCs from patients with active cGVHD.

From: Wnt/β-catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients

Fig. 4

A Representative protein expression of Wnt3a, phosphor-GSK-3β, total-GSK-3β, phosphor-β-catenin, total-β-catenin, and β-tubulin in MSCs derived from healthy donors, patients without cGVHD, patients with mild-cGVHD and patients with moderate/severe cGVHD. B Relative protein expression of HD-MSCs, no cGVHD-MSCs, and active cGVHD-MSCs. C Relative protein expression of MSCs with different severities of cGVHD.Protein expression was normalized within each sample to the internal reference protein β-tubulin. HD-MSCs (n = 7), no cGVHD-MSCs (n = 33), mild cGVHD-MSCs (n = 8), and moderate/severe cGVHD-MSCs (n = 25). Black bars in each figure represent the median ± range. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Back to article page